Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.
about
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibitionEpigenetics in Brain Tumors: HDACs Take Center StageSAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophyCancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitorPhase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic gliomaLinking proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-induced signaling.Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group studyPhase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.Newly Identified Cancer-Associated Role of Human Neuronal Growth Regulator 1 (NEGR1)Histone deacetylase inhibitor upregulates peroxisomal fatty acid oxidation and inhibits apoptotic cell death in abcd1-deficient glial cells.Caffeine-mediated inhibition of calcium release channel inositol 1,4,5-trisphosphate receptor subtype 3 blocks glioblastoma invasion and extends survival.Vorinostat-An Overview.Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study.Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.PPAR Gamma Activators: Off-Target Against Glioma Cell Migration and Brain Invasion.Epigenetic changes in gliomas.Molecular epigenetics and genetics in neuro-oncology.Epigenetics of neurological cancers.Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets.The good, the bad and the ugly: epigenetic mechanisms in glioblastoma.Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.Investigational new drugs for brain cancer.Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.HDAC inhibitor DWP0016 activates p53 transcription and acetylation to inhibit cell growth in U251 glioblastoma cells.Early prediction of response to Vorinostat in an orthotopic rat glioma model.Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.Dissection of mitogenic and neurodegenerative actions of cystine and glutamate in malignant gliomas.Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.PRG3 induces Ras-dependent oncogenic cooperation in gliomas.Increased expression of histone deacetylaces (HDACs) and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA.Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02.Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration.Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy.In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy.
P2860
Q24655533-5CA0A585-9EEA-4421-AC3D-8A17311533E6Q28080964-796DD0AD-E007-45C2-9EAD-2D13939F15C3Q28271235-1FD663C9-D5F6-49C6-952A-7089A721E23BQ28972517-4E97A611-1C2F-46BC-92B2-5B1589E29F02Q30300986-BC9857C0-ADF9-45F3-B0C0-29F2E5291EABQ30588679-5A9FA666-32E5-43AD-B0E8-A08FE7D44905Q33383828-BB077A01-510C-478D-9F01-897F78A6838FQ33397543-907F8341-5EAE-4603-8E18-87546EE4BD59Q33398291-6D5FC0A5-60D3-4CB6-B90E-BAF48173AD56Q33402978-C540312E-7B25-4B33-94BD-C5CFCCF43F75Q33827019-516D4848-EDE8-49C2-8B70-BFAD72148F8EQ33935244-BA2264A6-95AE-4EB3-9000-7CC2049F3EE3Q34907267-443D8183-3112-420E-A1D1-EA08A82E2B58Q35740983-603A69D6-7537-4C5A-8B6F-D281089B525FQ35944176-F6A240AF-AFD7-4133-8AD8-17CCF177AE89Q36026945-861E52A1-440D-45EA-AEAD-4B5C76B0192AQ36485991-455A2885-C65F-4896-9E08-0874435516A1Q36668246-216A15D6-F475-4185-8222-B2E63284EC68Q37278858-07BC364F-D55A-4DE6-A819-A290E135763FQ37287032-940CE618-7265-4A6C-A690-7CA24BBFDF38Q37533620-E030C1E3-A56E-4CCA-B186-BDE48E64B98FQ37650610-209B2F5D-5646-4426-AC93-7338FD17271BQ37937061-B02140BC-E923-4A72-AE89-534554611144Q38024560-DE030726-A5BF-4CDB-81D8-542AFFDE9FA5Q38340158-39679A70-B27C-43B0-ABD6-D42D0022C478Q38832510-0BCD3870-24CA-4693-9B63-0076EC4FD943Q38933860-D25D48C1-2454-443F-8002-93BEDCE8B8AEQ39214706-0383B993-8638-4B94-89E7-4C82FAA9B4B2Q39402126-7E0D0CE9-3D23-4374-931B-E0F891134EC1Q39539377-F6CBCE41-CDB2-42DB-A411-8565EBFC82C4Q39552807-254804F9-138F-49EB-AE92-3EB43EB6A520Q39662069-DC8FF281-6E9B-435A-8278-588265506F3EQ39987026-4CD6F1EA-59E3-49AB-8CD6-93977EDBC448Q40078610-0E2B3910-95AC-46B1-A05A-39FE6CB2645FQ41225581-57908F5A-A239-4F65-9767-A0CDE55CDA3EQ41881419-E1AA3AF8-150E-4B1F-ADCE-2FEE923D014FQ42696115-2A4B6BB6-8325-4A31-A8D1-203092EE9B8CQ42882263-8FEF4199-8894-4BB2-9EF3-67D11227A6A8Q43152628-EE733F0C-CF5B-416D-96E5-A5FF6C1B61DCQ48485610-A8B783F4-BB4C-42CA-AE3A-8C1519E0BFB2
P2860
Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Suberoylanilide hydroxamic aci ...... in vitro, ex vivo and in vivo.
@en
type
label
Suberoylanilide hydroxamic aci ...... in vitro, ex vivo and in vivo.
@en
prefLabel
Suberoylanilide hydroxamic aci ...... in vitro, ex vivo and in vivo.
@en
P2093
P2860
P50
P1476
Suberoylanilide hydroxamic aci ...... in vitro, ex vivo and in vivo.
@en
P2093
Christian Tränkle
Eric Hahnen
Ingmar Blümcke
Mike Lüders
Rolf Buslei
Rudolf Fahlbusch
P2860
P304
P356
10.1111/J.1471-4159.2005.03098.X
P407
P577
2005-05-01T00:00:00Z